New Immunotherapy for Small Cell Lung Cancer Impresses in Phase II Clinical Trial
Karl Landsteiner University of Health Sciences important study center. Data published in New England Journal of Medicine. Krems (Austria), 23. November 2023: Results from a recently published phase II clinical trial of an immunotherapeutic agent (Tarlatamab) for the treatment of small cell lung cancer have demo...